FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs

November 17, 2022 by Dan McCue
FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs
(Photo by Anna Dudkova via UnSplash)

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute onset of pancreatitis in dogs. 

Panoquell-CA1 is an injectable drug intended for use while the dog is hospitalized for treatment of the disease.  

Pancreatitis is a painful inflammatory disease of the pancreas that can be life-threatening and generally requires that dogs be hospitalized for treatment. In most cases, it occurs spontaneously. 

Common factors that increase the chance of developing pancreatitis include when dogs eat something outside of their normal diet (particularly fatty foods), treatment with certain medications, and diseases like diabetes mellitus, the FDA said.

It is more common in certain breeds of dogs and in some dogs may become a recurring or chronic condition. 

“This is the first drug to address a serious and life-threatening disease that previously could only be managed through supportive care, such as intravenous fluids, pain medication, antiemetics, and dietary rest,” said Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine, in a written statement. 

“The conditional approval pathway allows medications like Panoquell-CA1 to reach the marketplace more quickly, and in this case gives dogs suffering from acute onset of pancreatitis earlier access to a drug to manage this disease,”  he said.

Conditional approval means that, when used according to the label, the drug is safe and has a reasonable expectation of effectiveness. 

The initial conditional approval is valid for one year with the potential for four annual renewals. 

During this time, the animal drug sponsor – in this case Ishihara Sangyo Kaisha Ltd. – must demonstrate active progress toward proving substantial evidence of effectiveness for full approval. 

If the sponsor does not meet the requirements for substantial evidence of effectiveness at the conclusion of five years, the product can no longer be marketed.

Fuzapladib sodium, the active ingredient in Panoquell, has been approved since 2018 in Japan to improve clinical signs in the acute phase of pancreatitis in dogs, but not in the United States until Tuesday. 

The FDA reviewed data associated with fuzapladib’s use in Japan as part of its assessment of the application for conditional approval. 

The agency said veterinarians should advise owners about the possible side effects, which include loss of appetite, digestive tract disorders, respiratory tract disorders, liver disease and jaundice, before using the drug. 

It is also encouraging dog owners to work with their veterinarian to report any adverse events or side effects potentially related to the use of any drug, including Panoquell-CA1. 

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-
  • dogs
  • FDA
  • Pancreatitis
  • Panoquell-CA1
  • In The News

    Health

    Voting

    Regulation

    Oil and Gas Companies Must Pay More to Drill on Federal Lands

    WASHINGTON (AP) — Oil and gas companies will have to pay more to drill on federal lands and satisfy stronger... Read More

    WASHINGTON (AP) — Oil and gas companies will have to pay more to drill on federal lands and satisfy stronger requirements to clean up old or abandoned wells under a final rule issued Friday by the Biden administration. The Interior Department's rule raises royalty rates for... Read More

    The Biden Administration Will Require Thousands More Gun Dealers to Run Background Checks on Buyers

    WASHINGTON (AP) — Thousands more firearms dealers across the United States will have to run background checks on buyers when... Read More

    WASHINGTON (AP) — Thousands more firearms dealers across the United States will have to run background checks on buyers when selling at gun shows or other places outside brick-and-mortar stores, according to a Biden administration rule that will soon go into effect. The rule aims to close a loophole... Read More

    New EPA Rule Says 200 US Chemical Plants Must Reduce Toxic Emissions Likely to Cause Cancer

    WASHINGTON (AP) — More than 200 chemical plants nationwide will be required to reduce toxic emissions that are likely to... Read More

    WASHINGTON (AP) — More than 200 chemical plants nationwide will be required to reduce toxic emissions that are likely to cause cancer under a new rule issued Tuesday by the Environmental Protection Agency. The rule advances President Joe Biden’s commitment to environmental justice by delivering critical... Read More

    April 3, 2024
    by Dan McCue
    FDA Approves New Antibiotic for Three Different Uses

    WASHINGTON — The Food and Drug Administration on Wednesday approved the drug Zevtera for the treatment of adults with certain... Read More

    WASHINGTON — The Food and Drug Administration on Wednesday approved the drug Zevtera for the treatment of adults with certain bloodstream infections, those with acute bacterial skin and skin structure infections, and adult and pediatric patients 3 months to less than 18 years old with community-acquired... Read More

    Hospitals Must Obtain Written Consent for Pelvic and Similar Exams, the Federal Government Says

    Hospitals must obtain written informed consent from patients before subjecting them to pelvic exams and exams of other sensitive areas — especially... Read More

    Hospitals must obtain written informed consent from patients before subjecting them to pelvic exams and exams of other sensitive areas — especially if an exam will be done while the patient is unconscious, the federal government said Monday. New guidance from the U.S. Department of Health and Human... Read More

    Uranium Being Mined Near Grand Canyon as Prices Soar and US Pushes for More Nuclear Power

    The largest uranium producer in the United States is ramping up work just south of Grand Canyon National Park on... Read More

    The largest uranium producer in the United States is ramping up work just south of Grand Canyon National Park on a long-contested project that largely has sat dormant since the 1980s. The work is unfolding as global instability and growing demand drive uranium prices higher. The... Read More

    News From The Well
    scroll top